FER F 2006
K 653 HI
510(K) Summary
Submitter: Cynosure, Inc.
5 Carlisle Road
Westford, MA 01886

Contact: George Cho
Senior Vice President of Medical Technology

Date Summary Prepared: December 7, 2005

Device Trade Name: Cynosure YAG MIR Family Laser

Common Name: Medical Laser System

Classification Name: Instrument, surgical, powered, laser
79-GEX
21 CFR 878.4810

Equivalent Device: The Cynosure YAG Family laser

Device Description: The Cynosure YAG MIR Family laser is a Nd:YAG laser, having a
ND:YAG crystal rod as a lasing medium.

Laser activation is by footswitch or finger switch. Overall weight of
the laser is 285lbs, and the size is 41°x18°x32” (HxWxD).
Electrical requirement is 220 VAC, 30A, 50-60 Hz, single phase.

Intended Use: The Cynosure YAG MIR Family Laser is indicated for permanent hair
reduction and the treatment of vascular and pigmented lesions and
wrinkles.

Comparison: The Cynosure YAG MIR Family Laser has the same indications for
use, the same principle of operation, and similar wavelengths and
pulse energy range as the predicate device(s).

Nonclinical Performance Data: none

Clinical Performance Data: none

Conclusion: The CynosureY AG MIR Family Laser is a safe and effective device
for the indications specified.

Additional Information: none

g LC DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
Food and Drug Administration
_ 9200 Corporate Boulevard
rEB } 2006 Rockville MD 20850
Mr. George Cho
Senior Vice President
Medical Technology
Cynosure, Inc.
5 Carlisle Road .
Westford, Massachusetts 01886
Re: K053421
Trade/Device Name: Cynosure YAG MIR Family Laser
Regulation Number: 21 CFR 878.4810
Regulation Name: Laser surgical instrument for use in general and plastic surgery and in
dermatology
Regulatory Class: iI
Product Code: GEX
Dated: December 7, 2005
Received: December 9, 2005
Dear Mr. Cho:
We have reviewed your Section 510(k) premarket notification of intent to market the device
referenced above and have determined the device is substantially equivalent (for the indications
for use stated in the enclosure) to legally marketed predicate devices marketed in interstate
commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to
devices that have been reclassified in accordance with the provisions of the Federal Food, Drug,
and Cosmetic Act (Act) that do not require approval ofa premarket approval application (PMA).
You may, therefore, market the device, subject to the general controls provisions of the Act. The
genera! controls provisions of the Act include requirements for annual registration, listing of
devices, good manufacturing practice, labeling, and prohibitions against misbranding and
adulteration.
If your device is classified (see above) into either class II (Special Controls) or class TIL (PMA),
it may be subject to such additional controls. Existing major regulations affecting your device
can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA
may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA’s issuance of a substantial equivalence determination does not mean
that FDA has made a determination that your device complies with other requirements of the Act
or any Federal statutes and regulations administered by other Federal agencies. You must
comply with all the Act’s requirements, including, but not limited to: registration and listing (21
CER Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic
product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-10590.

Page 2 — Mr. Cho
This letter will allow you to begin marketing your device as described in your Section 510(k)
premarket notification. The FDA finding of substantial equivalence of your device to a legally
marketed predicate device results in a classification for your device and thus, permits your
device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please
contact the Office of Compliance at (240) 276-0115. Also, please noté the regulation entitled,
“Misbranding by reference to premarket notification” (21 CFR Part 807.97). You may obtain
other general information on your responsibilities under the Act from the Division of Small
Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or
(301) 443-6597 or at its Internet address http://www. fda.govw/cdrh/industry/support/index.htm].

Sjncerely yours,

lle ( nel)
ark N Melkerson
Acting Director
Division of General, Restorative
and Neurological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

510(k) Number (if known): K 0 5 34 a] _

Device Name: _Cynosure YAG MIR Family Laser

Indications For Use:

1064nm: The Cynosure YAG MIR Family laser is intended forthe coagulation and hemostasis of
benign vascular lesions, such as , but not limited to, port wine stains, hemangiomas, warts,
telangiectasia, rosacea, venus lake, leg veins, spider veins and poikiloderma of civatte, and treatment of
benign cutaneous lesions such as warts, scars, stiae and psoriasis. The laser is also intended for the
treatment of benign pigmented lesions such as, but not limited to, lentigos (age spots), solar lentigos (sun
spots), Café au lait macules, sebortheic keratoses, nevi, chloasma, verrucea, skin tags, keratoses, tattoos
(significant reduction in the intensity of black and/or blue/black tattoos) and plaques.

The laser is also indicated for the treatment of wrinkles such as, but not limited to, periocular and
perioral wrinkles.

Additionally, the laser is indicated for the removal of unwanted hair, for the stable long term, or
permanent, hair reduction through selective targeting of melanin in the hair follicles, and for the

' treatment of pseudofolliculitis barbae (PFB).

; 1440nm: The Cynosure YAG MIR Family laser is indicated for use in general surgery and dermatology
for the incision, excision, ablation, vaporization, coagulation and hemostasis of soft tissue. It is also
indicated for the treatment of periorbital and perioral wrinkles and pigmented lesions.

Prescriptive Use_ Xs OR Over-The-Counter Use
(Part 21 CFR 801 Subpart D) (Part 21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
: - Concurrence of CDRH, Office of Device Evaluation (ODE) _
tu w fs j
Division of i:eaeral., Resioraiive,
and Neuroluseal Devine
510(k) Number_£05 242\ _

